A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)
Status:
Not yet recruiting
Trial end date:
2022-12-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of
lazertinib in participants with impaired hepatic function when compared with healthy
participants with normal hepatic function, under fed conditions.